Australian company Neuren Pharmaceuticals (ASX:NEU) has received the upfront payment of US$100 million that was earned following the recent global expansion of its partnership with Acadia Pharmaceuticals for DAYBUE (trofinetide). …
Neuren receives US$100 million initial payment for expanded DAYBUE agreement
July 27, 2023 Australian Biotech
Latest Video
Georgia Forrest
New Stories
-
CSL expands US manufacturing with $1.5bn investment to boost plasma therapy production
March 10, 2026 - - Latest News -
Labor’s FoI backdown is a welcome victory for transparency and accountability
March 10, 2026 - - Latest News -
Mark Butler steps in to block eye injection funding change after patient warnings
March 10, 2026 - - Latest News -
Pharmac says new agreement has improved access to treatment for New Zealanders
March 10, 2026 - - Latest News -
Island Pharmaceuticals expands antiviral program through Burnet Institute collaboration
March 9, 2026 - -
New cancer research highlights potential of narmafotinib to koost KRAS Inhibitor therapies
March 9, 2026 - - Australian Biotech -
Lateral Pharma secures key U.S. patent for novel neuropathic pain therapy
March 9, 2026 - - Australian Biotech